Optimal duration of anticoagulant therapy

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 2, 2013, Pages 141-146

  Schulman, Sam ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

anticoagulation; hemorrhage; thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTE FUNCTION; TREATMENT DURATION;

EID: 84874193365     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1333542     Document Type: Article

References (39)

1. Lee A. Y., Levine M. N., Baker R. I., et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med: 2003; 349 2 146 153 (Pubitemid 36818784)
2. Hansen M. L., Sorensen R., Clausen M. T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med: 2010; 170 16 1433 1441
3. Landefeld C. S., Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med: 1989; 87 2 144 152 (Pubitemid 19201634)
4. Schulman S., Beyth R. J., Kearon C., Levine M. N. American College of Chest Physicians Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 6 (Suppl): 257S 298S (Pubitemid 351892969)
5. Eckman M. H., Rosand J., Knudsen K. A., Singer D. E., Greenberg S. M. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke: 2003; 34 7 1710 1716 (Pubitemid 36842632)
6. Majeed A., Kim Y. K., Roberts R. S., Holmström M., Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke: 2010; 41 12 2860 2866
7. Donzé J., Clair C., Hug B., et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med: 2012; 125 8 773 778
8. Schulman S., Beyth R. Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. Eur Heart J: 2005; 7 (Suppl C): C34 C40 (Pubitemid 40676584)
9. White R. H., McKittrick T., Takakuwa J., Callahan C., McDonell M., Fihn S. National Consortium of Anticoagulation Clinics Management and prognosis of life-threatening bleeding during warfarin therapy. Arch Intern Med: 1996; 156 11 1197 1201 (Pubitemid 26196247)
10. Kearon C., Kahn S. R., Agnelli G., Goldhaber S., Raskob G. E., Comerota A. J. American College of Chest Physicians Antithrombotic therapy for venous thromboembolic disease. Chest: 2008; 133 6 (Suppl): 454S 545S
11. Schulman S., Lindmarker P., Holmström M., et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost: 2006; 4 4 734 742
12. Douketis J. D., Gu C. S., Schulman S., Ghirarduzzi A., Pengo V., Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med: 2007; 147 11 766 774 (Pubitemid 351664441)
13. Kearon C., Akl E. A., Comerota A. J., et al. American College of Chest Physicians Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 2 (Suppl): e419S e494S
14. Dahri K., Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost: 2007; 98 5 980 987 (Pubitemid 350091126)
15. Holbrook A., Schulman S., Witt D. M., et al. American College of Chest Physicians Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 2 (Suppl): e152S e184S
16. Linkins L. A., Choi P. T., Douketis J. D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med: 2003; 139 11 893 900
17. Kearon C., Ginsberg J. S., Kovacs M. J., et al. Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med: 2003; 349 7 631 639 (Pubitemid 36975995)
18. Ridker P. M., Goldhaber S. Z., Danielson E., et al. PREVENT Investigators Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med: 2003; 348 15 1425 1434 (Pubitemid 36407171)
19. Schulman S., Eriksson H., Goldhaber S., et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J Thromb Haemost: 2011; 9 02 731 732 (Abstr. O-Thu-033)
20. Palareti G., Cosmi B., Legnani C., et al. PROLONG Investigators D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med: 2006; 355 17 1780 1789 (Pubitemid 44631361)
21. Verhovsek M., Douketis J. D., Yi Q., et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med: 2008; 149 7 481 490, W94
22. Eichinger S., Heinze G., Jandeck L. M., Kyrle P. A. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation: 2010; 121 14 1630 1636
23. Rodger M. A., Kahn S. R., Wells P. S., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ: 2008; 179 5 417 426
24. Tosetto A., Iorio A., Marcucci M., et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost: 2012; 10 6 1019 1025
25. Schulman S. Duration of Anticoagulation Study Group The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Wien Med Wochenschr: 1999; 149 2-4 66 69 (Pubitemid 29197568)
26. Connolly S. J., Ezekowitz M. D., Yusuf S., et al. RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
27. Granger C. B., Alexander J. H., McMurray J. J., et al. ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
28. Patel M. R., Mahaffey K. W., Garg J., et al. ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
29. Bauersachs R., Berkowitz S. D., Brenner B., et al. EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med: 2010; 363 26 2499 2510
30. Schulman S., Kakkar A. K., Schellong S., et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Proceedings of American Society of Hematology Conference, San Diego 2011:Abstr 205
31. Schulman S., Baanstra D., Eriksson H., et al. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost: 2011; 9 22(Abstr. O-Mo-037)
32. You J. J., Singer D. E., Howard P. A., et al. American College of Chest Physicians Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 2 (Suppl): e531S e575S
33. Mitchell L. B. CCS Atrial Fibrillation Guidelines Committee Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol: 2011; 27 1 91 97
34. Bishara R., Telman G., Bahouth F., Lessick J., Aronson D. Transient atrial fibrillation and risk of stroke after acute myocardial infarction. Thromb Haemost: 2011; 106 5 877 884
35. Calkins H., Brugada J., Packer D. L., et al. Heart Rhythm Society; European Heart Rhythm Association; European Cardiac Arrhythmia Society; American College of Cardiology; American Heart Association; Society of Thoracic Surgeons HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace: 2007; 9 6 335 379
36. Whitlock R. P., Sun J. C., Fremes S. E., Rubens F. D., Teoh K. H. American College of Chest Physicians Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 2 (Suppl): e576S e600S
37. Vandvik P. O., Lincoff A. M., Gore J. M., et al. American College of Chest Physicians Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 2 (Suppl): e637S e668S
38. Ageno W., Dentali F., Squizzato A., et al. Evidence and clinical judgment: treatment of cerebral vein thrombosis. Thromb Haemost: 2010; 103 6 1109 1115
39. Carrier M., Le Gal G., Wells P. S., Rodger M. A. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med: 2010; 152 9 578 589